Professor Qian JIANG, M.D.

Professor of International Medicine

Peking University People’s Hospital

Peking University Institute of Hematology

China

Medical education

• 1984-1990: M.D. Peking University Health Science Center

Clinical history

• 2017 - present: Chief Physician and Professor of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology
• 2010 - 2017: Chief Physician and Associate Professor of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology
• 2004 - 2010: Associate Chief Physician of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology
• 1996 - 2004: Attending Doctor of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology
• 1990 - 1996: Resident Physician of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology

Research interests

• Clinical research of CML, MPN, AML, ALL, and CLL

Dr Carolina Pavlovsky, MD

Fundaleu Hospital and Clinical Research Center

Buenos Aires, Argentina

Carolina Pavlovsky works as a hematologist at Fundaleu (Foundation to fight Leukemia) in Buenos Aires and serves as Head of the Research Department since 2010. She received her doctorate from the University of Buenos Aires and completed her training in internal medicine and hematology at the National Academy of Medicine in Buenos Aires.

Her main interests are chronic leukemias: molecular and clinical aspects. Since 2003, she has worked on multiple research protocols for chronic leukemias and is in charge of CML and CLL projects. Since 2005, she has coordinated an Argentine multi-center study on molecular monitoring in patients with CML and since 2011 she coordinates the clinical aspects of a new multi-centric study on mutational analysis of patients with CML and treatment failure. In June 2008, she undertook a training at the Department of Leukemias at the MD Anderson Cancer Center in Houston. In 2014 she obtained a Master's degree in Molecular Oncology from the National Cancer Research Center of Spain (CNIO) and the European School of Oncology (ESO).

Ricardo Teixeira Fernandes, M.D.

Executive Director of the OncoHemato Clinic

Rio de Janeiro, Brazil

Dr. Ricardo Teixeira is the Executive Director of the OncoHemato Clinic in Rio de Janeiro (Brazil). He specialized in medical oncology and clinical hematology according to the guidelines of the Brazilian Medical Association. He graduated in medicine at the School of Medicine at the Fluminense Federal University in Niterói in the State of Rio de Janeiro and made his residency at the Lagoa hospital in Rio de Janeiro. He undertook a visitorship at the M.D. Anderson Cancer Center and John Hopkins Hospital in the USA. He is fellow of the Oncological Institute of the Gregorio Marañón Hospital of the Complutensis University and Master in Palliative Medicine (Madrid Autonoma University in Madrid, Spain). Dr Teixeira used to be chief of the Clinic of Medical Oncology and Clinical Hematology in the São Paulo Air Hospital and Chief at the Bonsucesso General Hospital in Rio de Janeiro.

Dr. Teixeira has published many articles on various subjects in clinical hematology and medical oncology in important international periodics. His last publication was the official publication of the Mexican Hematology Society about CML. He participated in the first clinical trial with Mitoxantrone in Brazil.

Dr. Texeira has recently undertaken a 4-weeks preceptorship at the Leukemia Department in M.D. Anderson Cancer Center (University of Texas). He will disseminate the preceptorship program of the iCMLf in Brazil in order to offer this training to young hematologists. 

Francisco Cervantes, MD, PhD

Hematology Department

Hospital Clínic

University of Barcelona

Barcelona, Spain

Dr Francisco Cervantes is senior consultant at the Hematology Department of the Hospital Clínic of Barcelona and professor at the University of Barcelona. His scientific interest has been focused on the study of chronic myeloid leukemia (CML) and the Ph-negative chronic myeloproliferative neoplasms (MPNs), mainly their natural history, prognosis, biology, and treatment. As a result of the activity in this field, he has published over 300 articles in peer-review journals. He was coauthor of the publications of the IRIS study that allowed the approval of imatinib as frontline treatment of CML, participated in the introduction of the second-generation tyrosine kinase inhibitors, and is a member of the expert panels of the European LeukemiaNet for CML and MPN treatment. In the MPN field, he was the leading author of the prognostic classification of primary myelofibrosis or IPSS. Dr Cervantes is a member of the American Society of Hematology, the European Hematology Association, the International Working Group for MPN Research and Treatment, the European LeukemiaNet, and the PETHEMA Spanish Collaborative Group.